It might be helpful to mitigate A-beta plaques, but it's not sufficient for addressing AD.
Potential for Combination: * Immune Education: If DCVax technology were adapted for neurodegeneration (a concept sometimes called "Neuro-Vaccines"), the dendritic cells could be "educated" to recognize and clear pathological proteins like Amyloid-beta or Tau, rather than tumor antigens. Sequential Therapy: A combination could involve VHB937 priming the brain's immune environment to be more receptive, followed by a personalized DC-based approach to specifically target the clearance of plaques.
A-beta plaque buildup is a natural protective response to cellular dysfunction; therefore, mitigating it will not address the upstream neurological issue. It's like removing puss from an infection; you still have the infection. It's why the MABs are not effective solutions to AD, and worse, they can cause brain swelling and bleeding... and they're very expensive.
Anavex has a safe and effective approach for addressing AD at the cellular level, restoring cellular homeostasis in early AD diagnosis. Unfortunately, they ran into a political wall with the CHMP, which forced them to withdraw. The battle isn't over yet... they will eventually find a path to approval; hopefully, with the newly depoliticized FDA.
Hopefully, NWBO isn't experiencing similar political headwinds.
Market Data 
Markets 
AI
